Galecto Biotech

Galecto is focused on developing novel drugs for the treatment of fibrosis, inflammation, and cancer based on targeting galectins, a group of proteins shown to be involved in many disease processes. Galecto’s team of scientists and experts has shown in preclinical and clinical studies that the company’s high potency galectin modulators may open new treatment possibilities for many patients. The company’s lead product, TD139, is an inhaled galectin-3 inhibitor in phase 2/3 studies for the treatment of idiopathic pulmonary fibrosis (IPF). Galecto is located in Copenhagen, Denmark
 
 
Galecto Biotech portfolio Ysios Capital
 

Details
Galecto Biotech
Cobis
Ole Maaloes Vej 3
DK-2200 Copenhagen N
Denmark
www.galecto.com